Literature DB >> 29157955

Development of a goat model for evaluation of withaferin A: Cervical implants for the treatment of cervical intraepithelial neoplasia.

Leslie C Sherwood1, Farrukh Aqil2, Manicka V Vadhanam3, Jeyaprakash Jeyabalan3, Radha Munagala2, David Hoetker4, Sanjay Srivastava5, Inder P Singh6, Scott Cambron7, Martin O'Toole7, Wendy Spencer8, Lynn P Parker9, Ramesh C Gupta10.   

Abstract

Cervical cancer is caused by human papillomavirus (HPV). The disease develops over many years through a series of precancerous lesions. Cervical cancer can be prevented by HPV-vaccination, screening and treatment of precancer before development of cervical cancer. The treatment of high-grade cervical dysplasia (CIN 2+) has traditionally been by cervical conization. Surgical procedures are associated with increased risk of undesirable side effects including bleeding, infection, scarring (stenosis), infertility and complications in later pregnancies. An inexpensive, non-invasive method of delivering therapeutics locally will be favorable to treat precancerous cervical lesions without damaging healthy tissue. The feasibility and safety of a sustained, continuous drug-releasing cervical polymeric implant for use in clinical trials was studied using a large animal model. The goat (Capra hircus), non-pregnant adult female Boer goats, was chosen due to similarities in cervical dimensions to the human. Estrus was induced with progesterone CIDR® vaginal implants for 14days followed by the administration of chorionic gonadotropins 48h prior to removal of the progesterone implants to relax the cervix to allow for the placement of the cervical implant. Cervical implants, containing 2% and 4% withaferin A (WFA), with 8 coats of blank polymer, provided sustained release for a long duration and were used for the animal study. The 'mushroom'-shaped cervical polymeric implant, originally designed for women required redesigning to be accommodated within the goat cervix. The cervical implants were well tolerated by the animals with no obvious evidence of discomfort, systemic or local inflammation or toxicity. In addition, we developed a new method to analyze tissue WFA levels by solvent extractions and LS/MS-MS. WFA was found to be localized to the target and adjacent tissues with 12-16ng WFA/g tissue, with essentially no detectable WFA in distant tissues. This study suggests that the goat is a good large animal model for the future development and evaluation of therapeutic efficacy of continuous local drug delivery by cervical polymeric implants to treat precancerous cervical lesions.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Cervical cancer; Cervical dysplasia; Cervical polymeric implant; Goat model; Local drug delivery

Mesh:

Substances:

Year:  2017        PMID: 29157955      PMCID: PMC5746057          DOI: 10.1016/j.yexmp.2017.11.008

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  23 in total

1.  Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo.

Authors:  Silvia D Stan; Eun-Ryeong Hahm; Renaud Warin; Shivendra V Singh
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

2.  Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III.

Authors:  Mack T Ruffin; Joanne M Bailey; Daniel P Normolle; Claire W Michael; Mary E Bieniasz; David C Kmak; Elizabeth R Unger; Dean E Brenner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-12       Impact factor: 4.254

3.  Multi-layer polymeric implants for sustained release of chemopreventives.

Authors:  Farrukh Aqil; Jeyaprakash Jeyabalan; Hina Kausar; Shyam S Bansal; Ram J Sharma; Inder P Singh; Manicka V Vadhanam; Ramesh C Gupta
Journal:  Cancer Lett       Date:  2012-07-20       Impact factor: 8.679

4.  A Review of Current Animal Models for the Study of Cervical Dysplasia and Cervical Carcinoma.

Authors:  Luke I Larmour; Tom W Jobling; Caroline E Gargett
Journal:  Int J Gynecol Cancer       Date:  2015-10       Impact factor: 3.437

5.  Rapid and sensitive method for determination of withaferin-A in human plasma by HPLC.

Authors:  Pankaj Patial; Vikram Gota
Journal:  Bioanalysis       Date:  2011-02       Impact factor: 2.681

6.  Medicaid status and stage at diagnosis of cervical cancer.

Authors:  Cynthia D O'Malley; Sarah J Shema; Lisa S Clarke; Christina A Clarke; Carin I Perkins
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

7.  A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy.

Authors:  S A Weiner; E A Surwit; V E Graham; F L Meyskens
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

8.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.

Authors:  Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg
Journal:  Lancet Oncol       Date:  2008-04-11       Impact factor: 41.316

9.  Bovine milk-derived exosomes for drug delivery.

Authors:  Radha Munagala; Farrukh Aqil; Jeyaprakash Jeyabalan; Ramesh C Gupta
Journal:  Cancer Lett       Date:  2015-11-18       Impact factor: 8.679

10.  Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells.

Authors:  Silvia D Stan; Yan Zeng; Shivendra V Singh
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.